Meeting details menu

Meeting Authors
Meeting Abstracts
Keynote lectures
Oral communications
Poster presentations
Special symposia
Other

Acta Physiologica Congress

Back

Acta Physiologica 2006; Volume 186, Supplement 650
Joint Meeting of The German Society of Physiology and The Federation of European Physiological Societies 2006
3/26/2006-3/29/2006
Ludwig-Maximilians-University, Munich


INHIBITION OF ERYTHROCYTE CATION CHANNELS AND PHOSPHATIDYLSERINE EXPOSURE BY CATECHOLAMINES
Abstract number: PT05P-18

Gatz1 S, Lang1 PA, Akel1 A, Hermle1 T, Niemoller1 OM, Attanasio1 P, Huber1 SM, Wieder1 T, Lang1 F, Duranton1 C

1Eberhard-Karls-University of Tuebingen, Dept. of Physiology

Osmotic shock, oxidative stress and Cl- removal activate a non-selective Ca2+-permeable cation conductance in human erythrocytes. The entry of Ca2+ leads to activation of a scramblase with subsequent exposure of phosphatidylserine at the cell surface. In the present study, we explored whether activation of the non-selective cation conductance and subsequent phosphatidylserine exposure might be influenced by catecholamines. Removal of Cl- enhanced annexin binding and decreased forward scatter, effects significantly blunted by the b-agonist isoproterenol. Fluo-3 fluorescence measurements revealed an increase of cytosolic Ca2+ activity following Cl- removal, an effect again significantly blunted by isoproterenol exposure. Whole-cell patch-clamp experiments performed in Cl--free bath solution indeed disclosed a time-dependent inactivation of a non-selective cation conductance following isoproterenol exposure. Phenylephrine, dobutamine and dopamine similarly inhibited the effect of Cl- removal on annexin binding and forward scatter. In conclusion, several catecholamines inhibit the Cl- removal-activated Ca2+ entry into erythrocytes, thus preventing increase of cytosolic Ca2+ activity, subsequent cell shrinkage and activation of erythrocyte scramblase.

To cite this abstract, please use the following information:
Acta Physiologica 2006; Volume 186, Supplement 650 :PT05P-18

Our site uses cookies to improve your experience.You can find out more about our use of cookies in our standard cookie policy, including instructions on how to reject and delete cookies if you wish to do so.

By continuing to browse this site you agree to us using cookies as described in our standard cookie policy .

CLOSE